AllSight
Companies · EWTX · Pharmaceutical Preparations

Edgewise Therapeutics, Inc. (EWTX)

Edgewise Therapeutics, Inc. (EWTX) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.

Edgewise Therapeutics, Inc. (EWTX) stock — financials & valuation

Key numbers for Edgewise Therapeutics, Inc. (EWTX): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.

AllSight quality score: 36/100 — a percentile rank of Edgewise Therapeutics, Inc.’s fundamentals against Manufacturing peers, weakest on profitability. A quality ranking, not a price prediction.

Market cap$4.4B
EV / EBITDA-19.9×
Return on equity-44.0%
ROIC-58.3%
Debt / equity0.0×
Dividend yield0.0%

Is Edgewise Therapeutics, Inc. overvalued? P/B looks overvalued vs its 5-year range.

Independent of the events above — derived from Edgewise Therapeutics, Inc.’s own financial statements and shown as context, never as advice.

Aug 6, 2026
Quarterly loss misses estimates as Servier deal funds cardiovascular pivot
Related companies in Pharmaceutical Preparations
Open live on AllSight — the whole market, decoded →

About AllSight · Editorial standards & method · Contact